Bioxytran (OTC: BIXT) Develops Path-Breaking Bird Flu Treatment

The biotech sector continues to be one of the more sought-after sectors, and one of the companies that may be worth tracking today is Bioxytran Inc. (OTC: BIXT). The company was in sharp focus yesterday after it made an announcement with major news with regard to its bird flu treatment.

Path-Breaking Development

In a major development, Bioxytran yesterday announced that it had developed a potential pathbreaking product in tackling bird flu, clinically known as HPAI (highly pathogenic avian influenza). Bioxytran revealed that its galectin antagonist, which is soluble in water and currently in preclinical trials, could change the way outbreaks of bird flu could be managed in egg-laying chickens. Such a breakthrough would help in preventing the need for mass culling of chickens and thereby help keep the worldwide food supply chain safe.

Further Information

The company went on to add that the breakthrough constituted a major step in the right direction in Bioxytran’s fight against a range of viral diseases. It was further noted that the new product would target the virus directly, and that was the primary reason why it could revolutionize the space.

Major Quote

“This breakthrough represents a significant step forward in our mission to combat viral diseases,” said David Platt, CEO of Bioxytran Inc. “By targeting the virus directly, we can protect both animal health and the global food supply. Our galectin antagonists block the spike proteins outside the cell. This may stop the spread of the disease right away. Our peer-reviewed study showed that our carbohydrate-based galectin antagonists attach to viral spike proteins.

Technicals

+/- EMA(20)	0.11 (+56.36%)
+/- SMA(50)	0.09 (+91.11%)
+/- SMA(200)	0.1 (+72.00%)
5-Day Perf.	+63.81%
1-Month Perf.	+112.35%
3-Month Perf.	+95.01%
6-Month Perf.	+98.61%
YTD Perf.	+91.32%
1-Year Perf.	+45.76%
RSI(14)	71.12
ATR(14)	0.02
ADX(14)	26.57
Beta (5Y)	11.08